Given the importance of IFN-γ and CD8+ T cells to ICI anti-tumor immune responses (35), we focused on the less explored role of CD4+ T cells with the aim of identifying driving immune mechanisms that could be targeted in patients with cancer to reduce IrAEs while preserving efficacy. The gene discussed is CD4; the disease is neoplasm.